Olema Pharmaceuticals Dirección
Dirección controles de criterios 2/4
Olema Pharmaceuticals' El consejero delegado es Sean Bohen , nombrado en Sep 2020, tiene un mandato de 3.25 años. la remuneración anual total es $5.99M , compuesta por 10.3% salario y 89.7% primas, incluidas acciones y opciones de la empresa. posee directamente 0.27% de las acciones de la empresa, por valor de $1.66M . La antigüedad media del equipo directivo y del consejo de administración es de 3.3 años y 3.3 años respectivamente.
Información clave
Sean Bohen
Chief Executive Officer (CEO)
US$6.0m
Compensación total
| Porcentaje del salario del CEO | 10.3% |
| Permanencia del CEO | 3.6yrs |
| Participación del CEO | 0.3% |
| Permanencia media de la dirección | 3.6yrs |
| Promedio de permanencia en la Junta Directiva | 3.7yrs |
Actualizaciones recientes de la dirección
Recent updates
Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path
Mar 28Estimating The Fair Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
Mar 04
Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation
Nov 09We're Keeping An Eye On Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate
Jun 11Will Olema Pharmaceuticals (NASDAQ:OLMA) Spend Its Cash Wisely?
Mar 01Olema Oncology grants stock options for 58.3K shares
Oct 05We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate
Sep 13Olema Pharmaceuticals GAAP EPS of -$0.82 misses by $0.18
Aug 09Olema stock soars 12% as FDA grants fast track status to OP-1250 for breast cancer subtype
Jul 21We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Easily Afford To Drive Business Growth
May 29Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth
Feb 08Our Take On Olema Pharmaceuticals
Jan 05We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate
Sep 19We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Afford To Drive Business Growth
Jun 04Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth
Feb 19
Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$97m |
| Sep 30 2023 | n/a | n/a | -US$96m |
| Jun 30 2023 | n/a | n/a | -US$97m |
| Mar 31 2023 | n/a | n/a | -US$110m |
| Dec 31 2022 | US$6m | US$616k | -US$105m |
| Sep 30 2022 | n/a | n/a | -US$100m |
| Jun 30 2022 | n/a | n/a | -US$95m |
| Mar 31 2022 | n/a | n/a | -US$79m |
| Dec 31 2021 | US$3m | US$595k | -US$71m |
| Sep 30 2021 | n/a | n/a | -US$60m |
| Jun 30 2021 | n/a | n/a | -US$52m |
| Mar 31 2021 | n/a | n/a | -US$38m |
| Dec 31 2020 | US$11m | US$178k | -US$24m |
Compensación vs. Mercado: Sean($USD5.99M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD3.42M).
Compensación vs. Ingresos: La compensación de Sean ha aumentado mientras la empresa no es rentable.
CEO
Sean Bohen (56 yo)
3.6yrs
Permanencia
US$5,989,638
Compensación
Dr. Sean P. Bohen, M.D., Ph.D. has been a Director at AltruBio, Inc. He is the Chief Executive Officer and Director of Olema Pharmaceuticals, Inc. since September 2020 and serves as its President. He serve...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 3.6yrs | US$5.99m | 0.26% $ 1.6m | |
| Chief Operating & Financial Officer | 3.8yrs | US$2.27m | 0.87% $ 5.3m | |
| Chief Medical Officer | 2.3yrs | US$2.25m | 0.14% $ 872.0k | |
| Vice President of Investor Relations & Communications | less than a year | sin datos | sin datos | |
| Senior VP & Head of People | no data | sin datos | sin datos | |
| Chief Discovery & Non-Clinical Development Officer | 3.8yrs | US$200.00k | 1.33% $ 8.0m | |
| VP & Head of Clinical Pharmacology | no data | sin datos | sin datos | |
| Corporate Secretary | 3.6yrs | US$3.27m | sin datos | |
| VP of Finance & Controller | 1.3yrs | sin datos | sin datos |
3.6yrs
Permanencia media
55yo
Promedio de edad
Equipo directivo experimentado: OLMAEl equipo directivo de la empresa se considera experimentado (3.3 años de antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 3.6yrs | US$5.99m | 0.26% $ 1.6m | |
| Independent Director | 11.3yrs | US$106.94k | 0.69% $ 4.2m | |
| Independent Director | 3.7yrs | US$114.94k | 0.15% $ 910.1k | |
| Independent Chairperson of the Board | 3.7yrs | US$134.94k | 0% $ 0 | |
| Chairman of Scientific Advisory Board | 3yrs | US$11.81k | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 3.4yrs | US$92.94k | 0% $ 0 | |
| Independent Director | 4.1yrs | US$105.94k | 0% $ 0 | |
| Independent Director | 3yrs | US$97.94k | 0% $ 0 | |
| Independent Director | 5.8yrs | US$102.94k | 0% $ 0 | |
| Director | 17.7yrs | sin datos | 1.7% $ 10.3m |
3.7yrs
Permanencia media
62yo
Promedio de edad
Junta con experiencia: La junta directiva de OLMA se considera experimentada (3.3 años de antigüedad promedio).